A recent study that found there has been a massive increase in type 2 diabetes cases worldwide since 1990 is an indication ...

Novo Nordisk's valuation remains high, trading at a significant historical premium. Click here to see why NVO stock is a Sell ...

Continuing GLP-1 receptor agonist medications when undergoing an endoscopic procedure appeared safe in a meta-analysis.

Despite crowding in the next-gen weight loss space, Metsera has raised over $500 million since its April launch, indicating a ...

The Study will also include use of certain glucagon-like peptide-1 ("GLP-1") receptor specific antibodies detectable ... Such forward-looking statements are estimates reflecting the Company's best ...

Coverage for these medications varies widely across plans; while many employers cover GLP-1 for diabetes treatment, fewer ...

and taking the supplement before a meal is key to feeling your best. Over 1,000 shoppers have purchased the supplement this ...

In a practice-changing guideline reversal, medical societies advised on Tuesday that most patients do not need to stop taking ...

Glucagon-like peptide medications that treat Type 2 diabetes and weight management continue to grow in popularity, though ...

However, interest in GLP-1 drugs, particularly Ozempic, has also been fueled in part by social media discourse and ...